IP Verse

Immunogenic Mutant Peptide Screening Platform - EP3194970

The patent EP3194970 was granted to F Hoffmann LA Roche on Jul 28, 2021. The application was originally filed on Sep 10, 2015 under application number EP15772084A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3194970

F HOFFMANN LA ROCHE
Application Number
EP15772084A
Filing Date
Sep 10, 2015
Status
Granted And Under Opposition
Jun 25, 2021
Publication Date
Jul 28, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BISCHOF & PARTNER RECHTSANWALTE PARTNERSCHAFTSGESELLSCHAFT MBBApr 27, 2022-WITHDRAWN

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20040000474
DESCRIPTIONUS8349558
INTERNATIONAL-SEARCH-REPORTUS2010151492
INTERNATIONAL-SEARCH-REPORTUS2011257890
INTERNATIONAL-SEARCH-REPORTWO2012159643
INTERNATIONAL-SEARCH-REPORTWO2014012051

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Heemskerk et al., "Review The cancer antigenome", The EMBO Journal, (20130101), vol. 32, no. 2, pages 194 - 203, XP055923619
OPPOSITION- Kasuga, "Comprehensive Analysis of MHC Ligands in Clinical Material by Immunoaffinity-Mass Spectrometry", Methods in Molecular Biology, (20130601), vol. 1023, doi:10.1007/978-1-4614-7209-4_14, pages 203 - 218, XP055923628
OPPOSITION- Nelson et al., "Tumor-Specific Mutations as Targets for Cancer Immunotherapy", Experimental and Applied Immunotherapy, (20110101), doi:10.1007/978-1-60761-980-2_7, pages 151 - 172, XP055923636
OPPOSITION- Yadav et al., "Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing", Nature, London, vol. 515, no. 7528, doi:10.1038/nature14001, ISSN 0028-0836, pages 572 - 576, XP055364790
OPPOSITION- Newell et al., "Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells", Nature Biotechnology, New York, (20140201), vol. 32, no. 2, doi:10.1038/nbt.2783, ISSN 1087-0156, pages 149 - 157, XP055923615
OPPOSITION- Granados et al., "Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides", Nature Communications, (20140501), vol. 5, no. 1, doi:10.1038/ncomms4600, XP055923623
OPPOSITION- Rammensee et al., "HLA ligandome tumor antigen discovery for personalized vaccine approach", Expert Review of Vaccines, (20131001), vol. 12, no. 10, doi:10.1586/14760584.2013.836911, ISSN 14760584, pages 1211 - 1217, XP055144265

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents